Risk factors associated with post-traumatic stress symptoms following childbirth in Turkey

OBJECTIVE: this study examined factors associated with symptoms of post-traumatic stress (PTS) following childbirth in women with normal, low-risk pregnancies in Nigde, Turkey. DESIGN: a prospective longitudinal design where women completed questionnaire measures at 20+ weeks' gestation and 6-8 weeks after birth. SETTING: eligible pregnant women were recruited from nine family healthcare centres in Nigde between September 2013 and July 2014. PARTICIPANTS: a total of 242 women completed questionnaires at both time points. MEASURES: PTS symptoms were measured using the Impact of Event Scale-Revised (IES-R) 6-8 weeks after birth. Potential protective or risk factors of childbirth self-efficacy, fear of childbirth, adaptation to pregnancy/motherhood, and perceived social support were measured in pregnancy and after birth. Perceived support and control during birth was measured after birth. Demographic and obstetric information was collected in pregnancy using standard self-report questions. FINDINGS: PTS symptoms were associated with being multiparous, having a planned pregnancy, poor psychological adaptation to pregnancy, higher outcome expectancy but lower efficacy expectancy during pregnancy, urinary catheterization during labour, less support and perceived control in birth, less satisfaction with hospital care, poor psychological adaptation to motherhood and increased fear of birth post partum. Regression analyses showed the strongest correlates of PTS symptoms were high outcome and low efficacy expectancies in pregnancy, urinary catheterization in labour, poor psychological adaptation to motherhood and increased fear of birth post partum. This model accounted for 29% of the variance in PTS symptoms. CONCLUSIONS: this study suggests women in this province in Turkey report PTS symptoms after birth and this is associated with childbirth self-efficacy in pregnancy, birth factors, and poor adaptation to motherhood and increased fear of birth post partum. IMPLICATIONS FOR PRACTICE: maternity care services in Turkey need to recognise the potential impact of birth experiences on women's mental health and adaptation after birth. The importance of self-efficacy in pregnancy suggests antenatal education or support may protect women against developing post partum PTS, but this needs to be examined further

Les Toxines des staphylocoques d’origine animale. Préparation et titrage de la Toxine ß

La toxine staphylococcique ß, caractéristique des souches d’ori gine animale, peut être obtenue en quantité importante en milieu liquide, mais est très généralement associée à des quantités varia bles de toxine u, ce qui entraîne des difficultés considérables dans les titrages. Parmi les méthodes permettant d’obtenir la toxine ß isolée, la floculation spécifique de la toxine a effectuée sur une toxine mixte a ß est la meilleure, le chauffage ou 1 action du formol entraînant une perte importante en toxine ß

Sur un Vaccin antistaphylococcique combiné : Anatoxines α et ß et Vaccin microbien polyvalent

Pillet J., Orta B., Isbir S., Mercier P., Lemétayer . Sur un vaccin anlislaphylococcique combiné : anatoxines α et β et vaccin microbien polyvalent. In: Bulletin de l'Académie Vétérinaire de France tome 103 n°7, 1950. pp. 409-412

L-MYC gene polymorphism and risk of thyroid cancer

L-myc gene polymorphism is a representative genetic trait responsible for an individual’s susceptibility to several cancers. However, there have been no reports concerning the association between thyroid cancer and L-myc gene polymorphism. Aim: To analyze the distribution of L-myc gene polymorphism in Turkish patients with thyroid disorders and thyroid cancers. Methods: We used a molecular genotyping method, polymerase chain reaction-based restriction fragment length polymorphism (PCR-RFLP). We studied 138 patients of whom 47 had multinodular goiter, 13 had follicular cancer and 69 had papillar cancer, in comparison with control group of 109 healthy individuals. Results: No significant difference in the distribution of genotypes was observed between thyroid patients and controls. Carrying SS or LS genotype revealed a 1.96-fold (95% CI 0.573–6.706) risk for the occurrence of follicular cancer when compared with controls, and 3.11-fold (95% CI 0.952–10.216), when compared with multinodular goiter patients (p = 0.04). Conclusion: We suggest that L-myc genotype profiling together with other susceptibility factors, may be useful in the screening for thyroid nodular malignancy.Для ряда опухолей человека показана корреляция между риском развития опухоли и определенным вариантом гена L-MYC. Данные о наличии такой связи при раке щитовидной железы к настоящему времени отсутствуют. Цель: проанализировать распределение полиморфных типов гена L-MYC в популяции больных с доброкачественными и злокачественными поражениями щитовидной железы, включая рак щитовидной железы, в Турции. Методы: для анализа полиморфизма гена L-MYC использован метод молекулярного генотипирования, в частности, метод определения полиморфизма длины рестрикционных фрагментов, основанный на полимеразной цепной реакции (PCR-RFLP). Определение проводили в лейкоцитах 138 больных, в том числе 48 больных с узловым зобом, 13 больных фолликулярным раком щитовидной железы и 69 больных папиллярным раком. Контрольную группу составляли 109 здоровых лиц. Результаты: статистически достоверных различий в распределении исследуемых генотипов у больных с патологией щитовидной железы и здоровых лиц не выявили. Показано, что относительный риск фолликулярного рака щитовидной железы у больных-носителей генотипа SS или LS составляет 1,96 по сравнению со здоровыми лицами (при 95% доверительном интервале от 0,573 до 6,706) и 3,11 по сравнению с больными с узловым зобом (при 95% доверительном интервале от 0,952 до 10,216) (р = 0,04). Выводы: по нашему предположению, определение профиля полиморфизма гена L-MYC с учетом других факторов, определяющих предрасположенность к развитию опухолей, может быть полезным при скрининге озлокачествления узелковых образований щитовидной железы